What should I know first?

Aripiprazole, the active medicine in Abilify, illustrates partial agonism. Its receptor effects depend on the target and experimental system.

This lesson uses UK Abilify tablet pharmacology. It does not carry over American indications or imply that oral and long-acting injectable products have identical licences.

This is a mechanism lesson, not a complete medicine guide. A diagram cannot choose treatment, predict your response, or tell you how to change a prescription.

How Brain Cells Communicate

An agonist activates a receptor. A partial agonist can activate it but produces a smaller maximum response than a full agonist in a defined experimental system. This describes an assay result, not a fixed percentage of a person’s dopamine activity.

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

No occupancy percentage or universal “dopamine balance” is shown. Receptor effects vary with context.
About this illustration

A full agonist is a reference for a larger maximum response in the same experimental system. No universal numerical response is assumed.

How the Medication Changes Signalling

The Abilify label describes partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors, with antagonist activity at serotonin 5-HT2A receptors. One medicine can have different actions at different receptor types.

A partial agonist can also compete with a fuller agonist at a receptor. The net effect depends on the surrounding signalling and the response being measured. It is not an automatic brain-wide “normaliser.”

A Closer Look at the Molecular Level

Known action: receptor experiments support context-dependent partial agonism. Studies of cloned human dopamine receptors investigate functional responses in particular experimental systems.

The UK product information proposes a combination of partial agonism and antagonism as the basis of therapeutic effects. This does not amount to a universal numerical fraction of dopamine activity. A half-filled symbol would suggest false precision, so this lesson uses words instead.

Sources and References

  1. Abilify 30 mg tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. What Is a Neurotransmitter?

    Scope: International scientific education; not UK regulatory evidence.

  3. Shapiro and colleagues: aripiprazole in cloned receptor systems

    Scope: International laboratory research.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top